Sublingual Cannabidiol for Anxiety

Completed · Phase 2 · Has a placebo group

Conditions studied: Anxiety

In brief

This is an open-label to double-blind study evaluating the effects of cannabidiol (CBD) for the treatment of anxiety in adults. Participants will use a sublingual (under-the-tongue) solution of whole plant-derived CBD or placebo three times daily for four weeks in addition to their normal treatment regimen. Participants' clinical state will be assessed weekly during the treatment period. In addition, cognitive function and measures of quality of life, sleep, and general health will be assessed at baseline and the post-treatment final visit.

Key facts

Study ID

NCT02548559

Run by

Staci Gruber, Ph.D.

People needed

46

Starts

2018-08-14

Expected to finish

2025-03-13

Last updated by the study team

2026-03-27

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• 18 or older
• Native English speaker or acquired English prior to age 5
• Provides informed consent
• Endorses moderate or severe anxiety at the screening visit

You may not qualify if…

• Non-native English speakers
• Estimated IQ < 75
• Pregnancy
• Presence of serious medical illness, including liver or kidney disease, neurological disorder, or certain psychiatric disorders
• History of head injury or loss of consciousness >5 minutes
• Current use of cannabis or cannabinoid products >1x/month

Where it is running

• McLean Hospital Brain Imaging Center — Belmont, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.